Phase 2b placebo-controlled RCT in 94 adults with moderate-severe chronic hand eczema resistant to potent topical steroids: 16 weeks of dupilumab improved severity and quality of life and largely restored skin barrier and immune gene programmes.
RCTn = 94
Gery et al. Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema